HaystackAnalytics secures patent for cutting-edge secure genomic analysis technology

New Delhi:  In a country like India, with a rapidly advancing healthcare landscape and a growing focus on equitable access to enhance disease diagnosis and personalized treatment,  HaystackAnalytics, a pioneer in genomics-based diagnostic solutions, has secured a patent for its groundbreaking invention, “Systems and Methods for Secure Genomic Analysis Using a Specialized Edge Computing Device.”

This patent marks a significant advance, enabling real-time genomic analysis at the point of use, reducing reliance on complex infrastructure and specialized personnel. It empowers laboratories and hospital labs with real time reporting capabilities with accurate, simplified and timely insights for enhanced patient diagnosis and treatment.

HaystackAnalytics holds exclusive rights to this patent for the next 20 years and is committed to integrating it into all its solutions while making it widely accessible. As genomic sequencing becomes more widespread, the lack of standardized analysis tools has been a major bottleneck. This patent allows real-time sequencing data analysis, minimizing dependence on bioinformatics experts and complex infrastructure.

Dr Anirvan Chatterjee, CEO & Co-founder, HaystackAnalytics said, “India is making big strides in biotech and genomics, and our patented technology is a game-changer. It enables faster, more accessible genomic analysis, improving rare disease diagnosis, AI-driven healthcare, and public health preparedness. By decentralizing disease surveillance and outbreak detection, we’re helping strengthen healthcare systems across the country. Our long-term vision is to create a seamless ecosystem where genomic insights can be leveraged effectively to improve patient outcomes and contribute to the global fight against infectious diseases and antimicrobial resistance.”

With rising concerns over antimicrobial resistance (AMR), tuberculosis (TB), and emerging infectious diseases, India urgently needs scalable genomic tools that can be seamlessly deployed in hospitals and labs without complex setup requirements. This milestone reinforces the company’s commitment to advancing genomic diagnostics, ensuring standardized, cutting-edge analysis is accessible across diverse healthcare settings. By collaborating with its network of 250+diagnostic labs, 100+ hospitals, and potential public and private healthcare partners, the IIT-B-based company aims to establish this technology as a cornerstone of precision medicine on a global scale.